NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
20/01/2026
Voltar para busca
Dado oficial do USPTO
NXERA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 35, 42, 44
Data de depósito
13/02/2024
Data de registro
20/01/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
20/01/2026
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
3
Tipo de titular
99
Localização do titular
TOKYO, JP
Examinador
DUBIN, DAVID I
Unidade examinadora
L70
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the stylized wording "NXERA" featured in black positioned within a yellow rectangle design that is connected to a smaller yellow rectangle design positioned to the right of the larger rectangle design that features a black flag design within the smaller rectangle design. The stylized wording and design, as illustrated in the mark, are positioned on top of a transparent rectangular background. The color white represents background, outlining, shading, and transparent areas and is not claimed as a feature of the mark.
Titulares e representantes
Titulares
NXERA PHARMA CO., LTD
Sosei Group Corporation
Representantes
Eric Lamb Frost Brown Todd LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical products and proteins both for use in the manufacture of industrial chemicals and biological pharmaceutical products; chemical products being industrial chemicals and protein in raw material form for scientific and medical research being research of chemical and biological pharmaceutical products; chemical products being industrial chemicals and proteins for industrial use in the field of diagnostic useexcept medical or veterinary uses; protein for industrial use and G-protein coupled receptors being protein for industrial use for manufacturing pharmaceutical products; protein for industrial use and G-protein-coupled receptors being protein for industrial use for the research of pharmaceutical products; industrial chemicals and protein for industrial use for use in the fields of chemical and biological drug discoverylead identification and diagnostics; protein for industrial use and G-protein-coupled receptors being protein for industrial use for drug discovery purposes; industrial chemicals and biologicals in the nature of protein for industrial usetransmembrane proteins and G-proteins both being protein for industrial useG-protein-coupled receptors being protein for industrial usefragments thereof being sequences of amino acids in the nature of amino acidsother than for medical or veterinary purposesfor use in the fields of chemical and biological drug discoverylead identification and diagnostics; protein for industrial use in the nature of transmembrane proteins and G-proteins both being protein for industrial useG-protein-coupled receptors being protein for industrial usefragments thereof being sequences of amino acids in the nature of amino acidsother than for medical or veterinary purposesfor use in the fields of pharmaceutical research and drug discovery purposes
Classe 5
Pharmaceutical preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicines for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological products for medical purposesmedicinal preparations being G-protein-coupled receptors for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the fields of chemical and biological drug discoverylead identificationdiagnostics and therapeutic purposes; biological and chemical products for medical useprotein supplements; biological and chemical products for medical usemedicinal preparation being G-protein-coupled receptors for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical usemedicinal preparation being transmembrane proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical usemedicinal preparation being G-proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; biological and chemical products for medical useantibodies for medical purposes and synthetic peptides and parts thereof being synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; chemical reagents for medical use and protein supplements for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of medical diagnostics; biological products being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of chemical and biological drug discoveryin the field of lead identification and diagnostics; biological products being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for therapeutic purposes; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of developing chemical and biological pharmaceutical products; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of identifying lead chemical and biological products; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for diagnostic use; biological formulation being medicinal preparations for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for therapeutic use; protein supplements and medicinal preparations being G-protein-coupled receptorsboth for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders for use in the field of drug discovery purposes; biological reagents for medical purposes and medicinal preparations being small chemical entities for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being G-protein-coupled receptors for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being transmembrane proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; medicinal preparations being G-proteins for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; antibodies for medical purposes and synthetic peptides for therapeutic purposes for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; protein supplements for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders; antibodies for medical purposes and synthetic peptides for modulating G-protein-coupled receptorstransmembrane proteins and parts thereof for treating and preventing G-protein-coupled receptor-mediated and G-protein-coupled receptor-implicated diseases and disorders in the field of medical diagnostics
Classe 35
Business managementbusiness organization consultingbusiness administrationall provided in the fields of chemical productsbiological productspharmaceuticalsdesign and development of drugsdrug discovery; Business managementbusiness organization consultingbusiness administrationall provided in the field of pharmaceutical and biopharmaceutical research and developmentfield of technologies related to proteins and G-protein-coupled receptors; wholesale and retail store services featuring pharmaceuticalsbiological products and chemical and biological preparations
Classe 42
Drug discovery services and pharmaceutical discovery services being pharmaceutical research services; Biotechnology research; pharmaceutical research services; chemical and medical testing in the nature of testing of chemicals; researchdevelopmentadviceconsultancy and information servicesdesign and testing of new products for others; research and development services in the field of pharmaceutical preparations being pharmaceuticals and biopharmaceuticals and field of pharmaceutical preparations being technologies related to proteins and G-protein-coupled receptors; pharmaceutical research services in the fields of chemical and biological drug discovery and development; pharmaceutical research services and pharmaceutical products development for identifying lead chemical compounds; examination and research services being pharmaceutical research services in the field of medicinal and synthetic chemistry; scientific research and development services in the fields of creation of libraries and collections of biologicalschemicals and compounds; researchcreationdevelopmentscientific research and development in the field of chemical and biological drug targets for screening purposes; researchanalysis and examinationscientific research and development in the field of identification of compounds through automated screening processes; scientific research and development services in the field of chemical and biological pharmaceutical development; medical research laboratory services; provision of informationadvisory services and consultancy in connection with all of the aforesaid services
Classe 44
Pharmaceutical compounding services; pharmaceutical advice and medical and pharmaceutical consultation; providing information relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; medical and pharmaceutical consultation in the fields of researchcreationdevelopment and provision of chemical and biological drug targets for medical screening purposes; all of the aforesaid services provided in the field of drug discovery and field of use of G-protein- coupled receptors in the design and development of pharmaceutical products
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
20/01/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
02/12/2025
PUBO
PUBLISHED FOR OPPOSITION
02/12/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/11/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/10/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
31/10/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
31/10/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
31/10/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
31/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/07/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/07/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
23/07/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
25/06/2025
GNFR
FINAL REFUSAL E-MAILED
25/06/2025
CNFR
FINAL REFUSAL WRITTEN
25/06/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/02/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/02/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/12/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/12/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/12/2024
GNRT
NON-FINAL ACTION E-MAILED
02/12/2024
CNRT
NON-FINAL ACTION WRITTEN
02/12/2024
DOCK
ASSIGNED TO EXAMINER
16/07/2024
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/07/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
25/06/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/06/2024
NWAP
NEW APPLICATION ENTERED
13/02/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NXERA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.